发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Rimegepant for migraine. 治疗偏头痛的 Rimegepant。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.029
{"title":"Rimegepant for migraine.","authors":"","doi":"10.18773/austprescr.2024.029","DOIUrl":"10.18773/austprescr.2024.029","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"134-135"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sum of the parts: a cascade of adverse effects. 各部分的总和：一连串的负面影响。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.031
Jane Poon, Fiona Coombes, Ian Coombes
{"title":"Sum of the parts: a cascade of adverse effects.","authors":"Jane Poon, Fiona Coombes, Ian Coombes","doi":"10.18773/austprescr.2024.031","DOIUrl":"10.18773/austprescr.2024.031","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"125-128"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Achieving safe medication management during transitions of care from hospital: time for a stewardship approach. 在医院护理过渡期间实现安全用药管理：是时候采用管理方法了。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.034
Rohan A Elliott, Manya Angley, Deirdre T Criddle, Fatemeh Emadi, Shania Liu, Jonathan Penm
{"title":"Achieving safe medication management during transitions of care from hospital: time for a stewardship approach.","authors":"Rohan A Elliott, Manya Angley, Deirdre T Criddle, Fatemeh Emadi, Shania Liu, Jonathan Penm","doi":"10.18773/austprescr.2024.034","DOIUrl":"10.18773/austprescr.2024.034","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"106-108"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of occupational exposure to blood and body fluids in primary care. 初级保健中对职业性接触血液和体液的管理。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.037
Anna Pierce
{"title":"Management of occupational exposure to blood and body fluids in primary care.","authors":"Anna Pierce","doi":"10.18773/austprescr.2024.037","DOIUrl":"10.18773/austprescr.2024.037","url":null,"abstract":"<p><p>Primary care workplaces where occupational exposure to blood and body fluids may occur should have policies and procedures in place to manage such incidents. All healthcare workers should be immunised against hepatitis B and ideally should have documentation of their antibody response to vaccination. Knowledge of hepatitis B immune status helps streamline the response to any exposure. Most occupational exposures carry a low risk of transmission of bloodborne viruses, and management can often be undertaken in general practice. Urgent risk assessment and management is crucial. If postexposure prophylaxis for hepatitis B or HIV is required, the earlier it is given, the more likely it is to be effective. Two-drug HIV postexposure prophylaxis is now more accessible because generic formulations of the drug combination are available, and general practitioners can prescribe this on a private prescription.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"113-118"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
QUM revisited. 重温 QUM。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.036
John Dowden
{"title":"QUM revisited.","authors":"John Dowden","doi":"10.18773/austprescr.2024.036","DOIUrl":"10.18773/austprescr.2024.036","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"131"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Additional preconception considerations for patients with diabetes. 糖尿病患者孕前的其他注意事项。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.022
{"title":"Additional preconception considerations for patients with diabetes.","authors":"","doi":"10.18773/austprescr.2024.022","DOIUrl":"10.18773/austprescr.2024.022","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"95-96"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines Repurposing Program - supporting new uses for existing medicines. 药品再利用计划--支持现有药品的新用途。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.025
{"title":"Medicines Repurposing Program - supporting new uses for existing medicines.","authors":"","doi":"10.18773/austprescr.2024.025","DOIUrl":"10.18773/austprescr.2024.025","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"97"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality use of medicines: who owns it now? 药品使用质量：现在谁说了算？
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.018
Jonathan Dartnell, Darlene Cox, Paresh Dawda, Catherine Hill
{"title":"Quality use of medicines: who owns it now?","authors":"Jonathan Dartnell, Darlene Cox, Paresh Dawda, Catherine Hill","doi":"10.18773/austprescr.2024.018","DOIUrl":"10.18773/austprescr.2024.018","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"72-74"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New and emerging drug therapies for Alzheimer disease. 治疗阿尔茨海默病的新兴药物疗法。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.021
Louise M Waite
{"title":"New and emerging drug therapies for Alzheimer disease.","authors":"Louise M Waite","doi":"10.18773/austprescr.2024.021","DOIUrl":"10.18773/austprescr.2024.021","url":null,"abstract":"<p><p>Established drug therapies for Alzheimer disease (cholinesterase inhibitors and memantine) do not modify the disease course and provide only modest clinical benefit. Biomarker measures of amyloid, tau and neurodegeneration have been integral to Alzheimer disease clinical trials for biologic drugs, for patient selection and efficacy monitoring. At the time of writing, two monoclonal antibodies targeting the amyloid-beta protein (aducanumab and lecanemab) have been approved in the USA, and two agents (lecanemab and donanemab) are under evaluation by the Therapeutic Goods Administration in Australia. Clinical trials have demonstrated that monoclonal antibodies are effective at removing amyloid from the brain in people with early Alzheimer disease. Cognitive benefits are statistically significant, but do not achieve the minimal clinically important difference. Amyloid-related imaging abnormalities of vasogenic oedema and microhaemorrhages occur more frequently on treatment; although these are usually asymptomatic or transient, in some people they are serious or fatal. Targeting amyloid as a unimodal strategy is unlikely to be sufficient and future therapies may need to be multimodal, targeting multiple pathogenic pathways. The burden of dementia is greatest in the older population where mixed dementia pathology dominates; the relationship between biomarkers, clinical phenotype and pathology attenuates; and frailty and comorbidity impact cognition. This creates challenges in identifying effective therapies for the group where dementia is most prevalent.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"75-79"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Controversies in the management of community-acquired pneumonia in adults. 成人社区获得性肺炎治疗中的争议。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.024
Emily Tucker, Maeve O'Sullivan, Lisa Waddell
{"title":"Controversies in the management of community-acquired pneumonia in adults.","authors":"Emily Tucker, Maeve O'Sullivan, Lisa Waddell","doi":"10.18773/austprescr.2024.024","DOIUrl":"10.18773/austprescr.2024.024","url":null,"abstract":"<p><p>Community-acquired pneumonia (CAP) is a common infectious syndrome in Australia and a leading global cause of morbidity and mortality. It drives a significant amount of antimicrobial prescribing in Australia. Accurate assessment and stratification of CAP severity is important. However, adequate evaluation is challenging and controversy remains about the optimal method. <i>Streptococcus pneumoniae</i> is the most commonly identified bacterial pathogen causing CAP. As such, oral amoxicillin monotherapy is the mainstay of empirical therapy for low-severity CAP. The need to start empirical therapy for pathogens such as <i>Mycoplasma pneumoniae</i> and <i>Legionella</i> species in low-severity CAP remains controversial; evaluating the causative pathogen on clinical grounds alone is difficult. Oral antibiotics recommended for CAP (e.g. amoxicillin, doxycycline) have excellent bioavailability and may be used instead of intravenous therapy in some hospitalised patients. A duration of 5 days of antibiotic therapy is recommended in clinical practice guidelines for patients with uncomplicated CAP who meet stability criteria at follow-up.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"80-84"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信